Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for cardiovascular (CV) disease, and there is considerable evidence that lowering LDL-C reduces the risk of both CV events and mortality in patients with CV disease.[@bib1] Nonetheless, strategies for lowering LDL-C are often poorly adopted in clinical practice, and many patients fail to reach guideline-recommended levels.[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10] Thus, patients in routine practice may not receive similar benefits in CV risk reduction to those observed in clinical trials. Although statins remain the mainstay of dyslipidemia management, attainment of the recommended LDL-C levels can be difficult without use of combination therapy.[@bib11]

In the Canadian Heart Research Centre Diabetes Mellitus Status in Canada (DM-SCAN) survey,[@bib12] only 57% of patients with high CV risk and diabetes achieved the guideline-recommended LDL-C level of \< 2.0 mmol/L. Likewise, in the Canadian cohort of the **Dys**lipidemia **I**nternational **S**tudy (DYSIS Canada), only 63% of all patients with high CV risk had the recommended LDL-C levels.[@bib13] Even in a recently completed Alberta survey, 48.5% of patients with atherosclerotic CV disease receiving lipid-lowering treatment, with the majority on moderate/high-dose statin therapy, did not achieve an LDL-C \< 2.0 mmol/L.[@bib14]

The clinical implications of this type of care gap are significant and have been reported,[@bib15] providing projections for the number of CV morbidity and mortality events that can be prevented if Clinical Practice Guidelines (CPGs) are followed.[@bib16] The CV benefits of add-on therapy for LDL-C lowering have recently been confirmed[@bib17], [@bib18], [@bib19] and incorporated into the Canadian practice.

Thus, this **Qu**ality **E**nhancement **R**esearch **I**nitiative (QuERI) is an implementation science program[@bib20] addressing the underlying reasons and solutions for clinical inertia with educational intervention based on feedback to physicians on their management of dyslipidemia to support their decision making and choice of therapy to more optimally achieve the guideline-recommended LDL-C level in high-risk patients.[@bib21]

Methods {#sec1}
=======

The **G**uidelines **O**riented **A**pproach to **L**ipid Lowering (GOAL) Canada was an interventional program supported by Amgen Canada as an investigator-initiated study started in 2015 and coordinated by the Canadian Heart Research Centre, an academic research and education physician organization. The intervention studied was physician education on the implementation of Canadian guidelines.[@bib16] The educational intervention was applied at the end of each visit on the basis of data entry in the electronic case report form. Specifically, physicians were asked if they would add LDL-C--lowering therapy as recommended by the CPGs.[@bib16] If the management chosen was consistent with the recommendations,[@bib16] then no further intervention was applied. If the management chosen was not consistent with the recommendation, physicians were alerted to that as an extra screen shown in the electronic case report form and asked if they would modify their management, and if not to provide the most significant single reason as to why not. The primary end point was the proportion of patients achieving the CPG[@bib16] recommended level for LDL-C at the last available follow-up visit. The study was approved by central and institutional Research Ethics Board where appropriate, and all enrolled patients provided informed consent.

Invitations to participate were sent to 750 Canadian physicians across Canada from a proprietary Canadian Heart Research Centre list of physicians who participated in prior cholesterol-oriented data-collection exercises,[@bib12]^,^[@bib13]^,^[@bib21] and 248 were activated to enroll their patients. These physicians were asked to enroll at least 12 of their patients with clinical vascular disease, such as coronary artery disease, cerebrovascular disease, abdominal aortic aneurysm, or peripheral arterial disease, or familial hypercholesterolemia (FH) as defined in the CPG.[@bib16] Patients also had to have LDL-C \> 2.0 mmol/L despite maximally tolerated statin therapy (defined as having tried at least 2 statins, each at least on 2 reduced doses) for the last 3 months before enrollment. Physicians were asked to enroll sequential patients, although it is not possible to verify this. Exclusion criteria were participation in a clinical trial with masked (blinded) cholesterol-lowering therapy, ongoing treatment with PCSK9i, or prior participation in the GOAL Canada program. Levels of LDL-C and management thereof were assessed on 3 occasions: baseline and twice more approximately 4 to 6 months apart.

The sample size of 2500 patients was planned for on the basis of the experience and success with the DYSIS registry in Canada.[@bib13] The study was stopped prematurely when the investigator-initiated study grant was exhausted mainly because of the longer duration of enrollment. The prespecified primary end point was the proportion of patients achieving the recommended LDL-C level of \< 2.0 mmol/L.

Statistical analysis {#sec1.1}
--------------------

Continuous data are shown as means with standard deviation or medians with 25th and 75th percentiles, and categorical data are shown as frequencies and percentages. Group comparisons were made using the chi-square test or McNemar test and paired *t* test or Kruskal--Wallis test for discrete and continuous variables, respectively, where appropriate. We used repeated-measures analysis to perform univariate and multivariable regression to determine the outcome across the visits.

Results {#sec2}
=======

The GOAL Canada study stopped recruitment on December 31, 2018, and last follow-up on September 30, 2019. In total, 248 physicians across Canada (60% primary care and 40% specialists) were registered to participate, and 2027 patients were enrolled (58% were men; median age, 63 years): British Columbia, 169 patients; Alberta, 90 patients; Saskatchewan, 6 patients; Manitoba, 49 patients; Ontario, 1545 patients; Quebec, 108 patients; New Brunswick, 41 patients; and Nova Scotia, 19 patients. There were 18 patients whose enrollment violated protocol inclusion criteria, and these were removed from analysis. During follow-up for visit 2 (141 ± 133 days after enrollment) and visit 3 (176 ± 145 days after visit 2), 5 and 4 patients died, 45 and 21 patients withdrew consent, and 214 and 184 patients were lost to follow-up, respectively. In total, 2009 patients were followed, and their results are reported.

Demographic variables and comorbid conditions are summarized in [Table 1](#tbl1){ref-type="table"}, and CV medications are shown in [Table 2](#tbl2){ref-type="table"}, including the comparison based on whether the recommended LDL-C level was achieved. Those patients achieving the LDL-C \< 2 mmol/L were more likely to have coronary artery disease (along with CV medications) rather than FH, to be male and hypertensive, and to have a history of smoking or chronic kidney disease.Table 1Comorbid conditions at baseline and in those achieving or not achieving the recommended LDL-C levelOverall (N = 2009)LDL-C target not achieved at last available visit (N = 1138)LDL-C target achieved at last available visit (N = 871)*P*Age (y)[†](#tbl1fndagger){ref-type="table-fn"}63 (55, 71)62 (55, 71)63 (56, 70)0.12Gender, male57.9%51.6%66.3%\< 0.0001BMI (kg/m^2^)[†](#tbl1fndagger){ref-type="table-fn"}28.7 (25.4, 32.3)28.4 (25.1, 32.1)28.9 (26.0, 32.5)0.012Systolic blood pressure (mm Hg)[†](#tbl1fndagger){ref-type="table-fn"}128 (120, 138)128 (120, 140)128 (120, 136)0.27Diastolic blood pressure (mm Hg)[†](#tbl1fndagger){ref-type="table-fn"}78 (70, 82)78 (70, 82)78 (70, 81)0.32Coronary artery disease51.6%44.2%61.2%\< 0.0001Cerebrovascular disease8.2%8.3%8.2%0.93Peripheral arterial disease/abdominal aortic aneurysm10.3%9.8%11.0%0.35FH[∗](#tbl1fnlowast){ref-type="table-fn"}47.5%49.8%44.6%0.019Hypertension60.2%57.1%64.3%0.001Smoking history48.1%44.7%52.5%0.0006Diabetes mellitus35.2%34.4%36.3%0.39Chronic kidney disease8.1%9.3%6.5%0.024[^1][^2]Table 2Cardiovascular medications and in those achieving or not achieving the recommended LDL-C levelOverall (N = 2009)LDL-C target not achieved at last available visit (N = 1138)LDL-C target achieved at last available visit (N = 871)*P*ACE inhibitor38.2%34.1%43.5%\< 0.0001Angiotensin receptor blockers22.4%22.9%21.8%0.58Beta-blocker39.1%33.6%46.4%\< 0.0001Calcium channel blocker22.4%21.1%24.0%0.12Diuretic19.0%20.3%17.2%0.08Antiplatelet therapy61.3%55.5%68.8%\< 0.0001Anticoagulant therapy7.2%7.2%7.2%0.98[^3]

Baseline total cholesterol was 5.5 ± 1.4 mmol/L, LDL-C was 3.3 ± 1.3 mmol/L, non--high-density lipoprotein cholesterol was 4.1 ± 1.4 mmol/L, high-density lipoprotein cholesterol was 1.3 ± 0.4 mmol/L, and triglycerides were 2.0 ± 1.4 mmol/L. LDL-C was 3.0 ± 0.9 mmol/L among those with CV disease alone, 3.9 ± 1.5 mmol/L in those with FH alone, and 3.4 ± 1.3 mmol/L in those with both. Lipid-lowering therapy used at baseline was statin therapy in 76% (with 24% statin intolerant) and ezetimibe in 25%. Statins used most frequently were rosuvastatin (40%, mean daily dose 22 mg) and atorvastatin (28%, mean daily dose 48 mg). Patients achieving the recommended LDL-C level were more likely to not be statin intolerant (83.8% vs 70.7%, *P \<* 0.0001) and to be on high efficacy type and dose of statin (52.4% vs 35.9%, *P \<* 0.0001).

The use of additional lipid-modifying therapies during follow-up and the increase in the addition of recommended therapies (specifically the use of ezetimibe and PCSK9i) are shown in [Figure 1](#fig1){ref-type="fig"}. The proportion of patients achieving the Canadian Cardiovascular Society recommended LDL-C level of \< 2.0 mmol/L (primary end point) increased significantly to 41.7% and 50.8% in visits 2 and 3, respectively ([Fig. 2](#fig2){ref-type="fig"}). The mean LDL was 3.3 mmol/L at baseline (visit 1) and decreased significantly to 2.4 and 2.2 mmol/L, respectively, during the follow-up in visits 2 and 3 ([Fig. 3](#fig3){ref-type="fig"}).Figure 1The use of lipid-lowering therapy beyond statin therapy at baseline and during follow-up. BAS, bile acid sequestrant.Figure 2Proportion of patients achieving the recommended low-density lipoprotein cholesterol (LDL-C) level during follow-up (primary end point).Figure 3LDL-C at baseline and during follow-up. ANOVA, analysis of variance; LDL-C, low-density lipoprotein cholesterol.

Achievement of the recommended LDL-C level was associated with a more frequent use of recommended lipid-lowering therapy at the last available visit with ezetimibe (44.4% vs 33.0%, *P* \< 0.0001) and PCSK9i (38.6% vs 11.0%, *P* \< 0.0001). The reasons for not using the recommended therapy after the initial visit are shown in [Table 3](#tbl3){ref-type="table"}. The proportion of patients in whom physicians indicated at baseline that addition of ezetimibe was not needed achieved recommended LDL-C level less frequently than those for whom the decision was made to prescribe it during the next visit (34.7% vs 53.9%, *P* = 0.0006). The same comparison with respect to the use of PCSK9i did not show a difference (45.5% vs 46%, *P* = 0.93).Table 3Reasons provided by physicians for not changing therapy according to the guideline- based recommendationsReasons "why not"PCSk9 inhibitorEzetimibeVisit 1/baseline (N = 947)Visit 2 (N = 811)Visit 3 (N = 671)Visit 1/baseline (N = 915)Visit 2 (N = 583)Visit 3 (N = 461)Not needed27.120.718.922.120.422.1Patient refused24.841.244.132.540.539.9Will prescribe next visit18.410.96.914.08.45.7Cost26.223.924.99.35.83.9Comorbidities1.10.72.21.21.41.5Patient intolerant1.52.23.020.523.226.5Social constraint0.60.400.100.2Believe management is appropriate0.3000.30.30.2[^4]

Discussion {#sec3}
==========

In patients with established CV disease, LDL-C lowering is one of the safest and efficient ways of lowering the risk of future CV events, including CV and total mortality and myocardial infarction and stroke. Lowering of LDL-C by 1 mmol/L results in 20% reduction in CV mortality and 12% reduction in total mortality, as well as 22% reduction in all CV events over 5 years.[@bib1] Thus, a mean reduction of LDL-C of \> 1 mmol/L observed in GOAL Canada ([Fig. 3](#fig3){ref-type="fig"}), if sustained, has the potential to provide an important reduction of CV death. More than half of high-risk patients could experience the risk of CV event reduced significantly by achieving the recommended LDL-C level as a result of physician reminder.

On enrollment, 24% of patients were not on any statin therapy because of intolerance. The etiology of treatment inertia can be multifactorial, including a number of patient- and physician-associated factors.[@bib22] We and others[@bib15]^,^[@bib23], [@bib24], [@bib25] have demonstrated that treatment inertia is associated with unfavourable outcomes. The results of GOAL Canada indicate that both gaps in knowledge (eg, risk underestimation) and action (eg, "knowing the right thing but not doing it") are present ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}). Physician responses such as "additional treatment not needed" indicate a knowledge gap in approximately 20% of physicians and were associated with a significantly smaller proportion of patients achieving the recommended LDL-C level. On the other hand, the response "I will add therapy next visit" is indicative of an action gap in approximately 15% to 20% of physicians.

The impact of programs such as GOAL Canada is significant given the LDL-C reduction demonstrated and expected reduction in CV events associated with this lowering. Thus, clinician-oriented support tools addressing both knowledge and care gaps may be of value as an extension of professional guidelines, although widespread implementation of such approaches and cost-effectiveness have not been demonstrated. Application of the results from clinical trials as part of a general implementation science strategy suggests important and reasonably inexpensive benefits that may be realized by programs such as GOAL Canada. Some of this benefit is clearly generalizable to other physician practices in Canada and may be realized by leveraging already implemented (and paid for) use of electronic medical records as a platform for clinical decision-making support.

Study limitations {#sec3.1}
-----------------

Selection bias at the physician and patient level may limit the generalizability of our findings. The educational intervention was not applied at the time of the clinical encounter itself, that is, it was possible for physicians to enter the data at some later point. This was the reason for one of the choices being, "I will follow the guidelines during the next visit." However, this does not detract from our overall implementation goal as demonstrated by clinically relevant increases in the proportion of patients achieving the guideline-recommended LDL-C level. Physician exposure to the educational intervention was not randomized; moreover, physicians may have received additional information or education regarding lipid lowering from other sources, which therefore limits the reliability or reproducibility of findings, and the results should be considered as hypothesis generating. A relatively short duration of follow-up did not allow assessment of the durability of the observed lowering in LDL-C levels.

Conclusion {#sec4}
==========

The results of the GOAL Canada program indicate the feasibility of overcoming treatment inertia and improving LDL-C control, which should help to achieve reduction in CV morbidity and mortality of Canadian patients.
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[^1]: In those with FH, 16% also had CV disease.

[^2]: Median (25th, 75th) percentiles.

[^3]: ACE, angiotensin-converting enzyme; LDL-C, low-density lipoprotein cholesterol.

[^4]: Number is expressed as percentage based on available (N) reasons.
